Exploring DVAI for your organisation? Arrange a confidential, no-obligation discussion. Confidential discussion
Pharma Agents · Cluster 5 of 5

Commercial & medical affairs

The commercial and medical-affairs edge — field-force prep against compressing HCP access, MSL insight capture, pre-MLR compliance triage, market-access dossier synthesis, and non-clinical patient-support tracking. Every agent operates under the ABPI/EFPIA/FDA promotional firewall: it never generates promotional copy autonomously, makes off-label claims, or gives clinical advice.

Use case 511

Field-force prep & HCP-access optimiser

The pain point

Face-to-face access to healthcare professionals has permanently compressed: Veeva Pulse data show just 45% of HCPs are now accessible to reps (down from 60% in 2022), and half of those limit themselves to three or fewer companies.59 Reps have narrower windows than ever to deliver value.

Promotional-conduct boundary. Under the ABPI/EFPIA/FDA codes governing pharmaceutical promotion, this agent does not generate customer-facing promotional copy autonomously, communicate any unapproved or off-label claim, or give clinical advice. It works only from approved, current material, preserves the medical/commercial firewall, and surfaces and structures information for human verification and sign-off. Every promotional and medical decision remains with the qualified human.
Impact — organisation

Shrinking, more selective HCP access; wasted preparation time; the risk of a generic or off-plan interaction burning a scarce meeting.

Impact — customer / client

For the HCP, less time and lower tolerance for anything not immediately relevant and compliant.

How it’s addressed

The agent gives reps hands-free briefings drawn only from currently-validated local brand plans and approved CRM history, so each scarce interaction is well-prepared and on-plan. It is read-only over approved material and structurally prevented from recommending or generating any unvetted clinical or promotional statement.

The benefits
Organisation

Designed to make each narrowing HCP window count by preparing reps from approved, current material — never surfacing generic or unapproved talking points.

Customer / client

For the HCP, a precise, relevant, compliant interaction that respects their limited time.

Use case 512

MSL scientific-insight capture

The pain point

Medical Science Liaisons gather crucial scientific feedback in peer-to-peer discussions with key opinion leaders, but manually entering nuanced qualitative notes into a CRM is slow and leads to delayed, diluted or incomplete capture.

Promotional-conduct boundary. Under the ABPI/EFPIA/FDA codes governing pharmaceutical promotion, this agent does not generate customer-facing promotional copy autonomously, communicate any unapproved or off-label claim, or give clinical advice. It works only from approved, current material, preserves the medical/commercial firewall, and surfaces and structures information for human verification and sign-off. Every promotional and medical decision remains with the qualified human.
Impact — organisation

Valuable scientific insight lost or delayed; MSL time split between listening and note-taking; medical-affairs HQ starved of structured field intelligence.

Impact — customer / client

For the KOL, an MSL half-focused on their laptop rather than the scientific dialogue.

How it’s addressed

The agent turns the MSL’s post-discussion spoken download into a structured summary using a specialised clinical vocabulary, presented to the MSL to edit before saving. Critically, it keeps these scientific insights segregated from the commercial sales team to preserve the medical/commercial firewall.

The benefits
Organisation

Designed to capture nuanced scientific insight quickly and accurately — with the MSL verifying every record and the medical/commercial firewall preserved by design.

Customer / client

For the KOL, an MSL fully present for the scientific conversation.

Use case 513

Pre-MLR material compliance triage

The pain point

Marketing teams spend substantial time shepherding promotional assets through mandatory Medical, Legal and Regulatory (MLR) review. Assets are repeatedly delayed by basic, avoidable errors — missing safety footnotes, incorrect warning formatting, outdated citations.

Promotional-conduct boundary. Under the ABPI/EFPIA/FDA codes governing pharmaceutical promotion, this agent does not generate customer-facing promotional copy autonomously, communicate any unapproved or off-label claim, or give clinical advice. It works only from approved, current material, preserves the medical/commercial firewall, and surfaces and structures information for human verification and sign-off. Every promotional and medical decision remains with the qualified human.
Impact — organisation

Slow time-to-market for approved materials; MLR panels’ time consumed by low-level rework; repeated revision cycles between marketing and reviewers.

Impact — customer / client

For the HCP or patient, slower access to accurate, approved educational material.

How it’s addressed

The agent runs a preliminary "compliance spellcheck", flagging potential deviations against pre-programmed ABPI/FDA rule sets before the asset reaches the panel. It is explicitly preliminary: it cannot approve any content for distribution — final sign-off rests entirely with the human MLR panel, and teams are warned not to treat a clean pass as approval.

The benefits
Organisation

Designed to catch avoidable, low-level compliance errors before MLR review, reducing rework — explicitly a pre-check, never an approval, with human MLR sign-off unchanged.

Customer / client

For the HCP or patient, accurate approved materials reaching them faster.

Use case 514

Market-access & value-dossier synthesis

The pain point

Securing formulary inclusion means assembling dense dossiers for payers and regional boards, with market-access managers spending weeks manually pulling from health-economics (HEOR) databases. Across pharma commercial functions, McKinsey estimates gen AI could unlock $18–30bn in value.58

Promotional-conduct boundary. Under the ABPI/EFPIA/FDA codes governing pharmaceutical promotion, this agent does not generate customer-facing promotional copy autonomously, communicate any unapproved or off-label claim, or give clinical advice. It works only from approved, current material, preserves the medical/commercial firewall, and surfaces and structures information for human verification and sign-off. Every promotional and medical decision remains with the qualified human.
Impact — organisation

Weeks of skilled market-access time on manual document assembly; slow payer submissions; the risk of misrepresenting a clinical endpoint under time pressure.

Impact — customer / client

For the payer, slower receipt of the evidence they need to make a decision.

How it’s addressed

The agent compiles already-approved clinical and economic studies into structured dossier drafts, operating only on direct-text extractions with verified citations linked back to the peer-reviewed source — never modifying study design, endpoints or outcomes statements. It aggregates approved evidence; it does not reinterpret it.

The benefits
Organisation

Designed to compress dossier assembly from approved sources — every figure citation-linked and unmodified — so market-access teams reach a reviewable draft faster.

Customer / client

For the payer, concise, well-structured, evidence-backed arguments sooner.

Use case 515

Patient Support Programme non-clinical tracker

The pain point

Patient Support Programmes for complex specialty drugs struggle with high early dropout, and nursing teams spend disproportionate time on routine administrative check-ins rather than complex clinical support.

Promotional-conduct boundary. Under the ABPI/EFPIA/FDA codes governing pharmaceutical promotion, this agent does not generate customer-facing promotional copy autonomously, communicate any unapproved or off-label claim, or give clinical advice. It works only from approved, current material, preserves the medical/commercial firewall, and surfaces and structures information for human verification and sign-off. Every promotional and medical decision remains with the qualified human.
Impact — organisation

Nurse capacity absorbed by logistics; high early-stage programme dropout; less time for the patients who most need clinical support.

Impact — customer / client

For the patient, inconsistent non-clinical support — and, if handled carelessly, a safety risk if a clinical issue is missed.

How it’s addressed

The agent handles non-clinical logistics only — delivery, refills, onboarding admin — with highly sensitive keyword triggers that instantly route any mention of a side effect or request for medical advice to a human clinical team. Its scope is strictly operational: it never gives medical guidance, adjusts dosages or interprets symptoms.

The benefits
Organisation

Designed to free nursing teams from routine administration for high-need patients — with hard, immediate escalation to humans on anything clinical, and no medical guidance ever given by the agent.

Customer / client

For the patient, consistent non-clinical support and an instant human handoff the moment anything clinical arises.

Previous cluster Regulatory & audit readiness

See how these map onto your organisation. Request a confidential discussion.

Get started
Confidential discussion

Talk to our Customer Success Team.

Take it further with a confidential, no-obligation discussion to scope a pilot in your environment.

Private & no-obligation

Every enquiry is held in confidence. We’ll walk you through the use cases relevant to you and scope how a sovereign deployment would work in your environment — with no obligation to proceed.

Request a meeting with the CST

We aim to respond within one working day.

Held in confidence · no obligation

Sources & references

Statistics describe demand and conditions across the relevant sector and are drawn from the cited public sources. They characterise the sector-level problem these agents address; they are not performance claims for any DVAI product. Deep Voice AI Limited is a pre-revenue company and makes no representation as to outcomes for any individual organisation. Figures are current as at the date of the cited publications.

Capable AI, on your terms — not the cloud’s.

Products
Business Agents
Company
Legal